IP Library › Granted Patent US 10,947,560
Granted Patent B2
US 10,947,560 · App. 15/700,279 · Granted Mar 16, 2021

Modified serotype 28 adenoviral vectors

Inventors: Lisa Wei (Gaithersburg, MD); Douglas E. Brough (Gaithersburg, MD); C. Richter King (New York, NY)
Assignee: GenVec, Inc.
C12N15/86A61K48/0008A61K48/00C12N2710/10021C12N2710/10043C12N2710/10322C12N2710/10343C12N2710/10345C12N2710/16634C12N2810/6018
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,947,560
App. No.
15/700,279
Granted
Mar 16, 2021
Kind
B2
Abstract

The invention provides a replication-deficient serotype 28 adenoviral vector characterized by comprising a portion of a serotype 45 adenoviral hexon protein and/or a portion of a serotype 45 fiber protein in place of the endogenous serotype 28 hexon and/or fiber protein.

Claims (36)

1. A replication-deficient serotype 28 adenoviral vector comprising a nucleic acid encoding (i) an immune response-inducing antigen and (ii) chimeric hexon and fiber proteins selected from the group consisting of:

(a) a chimeric hexon protein comprising a portion of an adenovirus serotype 45 hexon protein in place of a corresponding portion of the endogenous serotype 28 hexon protein, wherein the portion of adenovirus serotype 45 hexon protein consists of the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence that is at least 95% identical to SEQ ID NO: 1;

(b) a chimeric fiber protein comprising a portion of an adenovirus serotype 45 fiber protein in place of a corresponding portion of the endogenous serotype 28 fiber protein, wherein the portion of an adenovirus serotype 45 fiber protein consists of the amino acid sequence of SEQ ID NO: 3 or an amino acid sequence that is at least 95% identical to SEQ ID NO: 3; and

(c) the chimeric hexon protein of (a) and the chimeric fiber protein of (b),

wherein the adenoviral vector requires complementation of a deficiency in one or more early regions of the adenoviral genome for propagation and does not require complementation of any other deficiency of the adenoviral genome for propagation.

2. The replication-deficient serotype 28 adenoviral vector of claim 1 , which comprises (c) the chimeric hexon protein of (a) and the chimeric fiber protein of (b).

3. The replication-deficient serotype 28 adenoviral vector of claim 1 , wherein the portion of adenovirus serotype 45 hexon protein is encoded by the nucleic acid sequence of SEQ ID NO: 2.

4. The replication-deficient serotype 28 adenoviral vector of claim 1 , wherein the portion of adenovirus serotype 45 fiber protein is encoded by the nucleic acid sequence of SEQ ID NO: 4.

5. The replication-deficient serotype 28 adenoviral vector of claim 1 , which comprises:

(a) an amino acid sequence of a serotype 28 adenovirus penton protein,

(b) an amino acid sequence of a serotype 28 adenovirus pIX protein,

(c) an amino acid sequence of a serotype 28 adenovirus p100 protein,

(d) an amino acid sequence of a serotype 28 adenovirus L1 52/55K protein, or

(e) any combination of (a)-(d).

6. The replication-deficient serotype 28 adenoviral vector of claim 1 , wherein the one or more early regions are selected from the group consisting of the E1 region, the E2 region, and the E4 region of the adenovirus genome.

7. The replication-deficient serotype 28 adenoviral vector of claim 6 , wherein the adenoviral vector requires complementation of a deficiency in the E1 region of the adenoviral genome for propagation and does not require complementation of any other deficiency of the adenoviral genome for propagation.

8. The replication-deficient serotype 28 adenoviral vector of claim 6 , wherein the adenoviral vector requires complementation of a deficiency in the E1A region or the E1B region of the adenoviral genome for propagation and does not require complementation of any other deficiency of the adenoviral genome for propagation.

9. The replication-deficient serotype 28 adenoviral vector of claim 6 , wherein the adenoviral vector requires at most complementation of a deficiency in the E4 region of the adenoviral genome for propagation and does not require complementation of any other deficiency of the adenoviral genome for propagation.

10. The replication-deficient serotype 28 adenoviral vector of claim 6 , wherein the adenoviral vector requires complementation of a deficiency in the E1 region of the adenoviral genome and a deficiency in the E4 region of the adenoviral genome for propagation and does not require complementation of any other deficiency of the adenoviral genome for propagation.

11. The replication-deficient serotype 28 adenoviral vector of claim 1 , which comprises the nucleic acid sequence of SEQ ID NO: 10.

12. A composition comprising the replication-deficient serotype 28 adenoviral vector of claim 1 and a pharmaceutically acceptable carrier.

13. A method of inducing an immune response, the method comprising administering to a mammalian subject the adenoviral vector of claim 1 , wherein the replication-deficient serotype 28 adenoviral vector comprises:

(a) a chimeric hexon protein comprising a portion of an adenovirus serotype 45 hexon protein in place of a corresponding portion of the endogenous serotype 28 hexon protein, wherein the portion of adenovirus serotype 45 hexon protein consists of the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence that is at least 95% identical to SEQ ID NO: 1; and

(b) a chimeric fiber protein comprising a portion of an adenovirus serotype 45 fiber protein in place of a corresponding portion of the endogenous serotype 28 fiber protein, wherein the portion of an adenovirus serotype 45 fiber protein consists of the amino acid sequence of SEQ ID NO: 3 or an amino acid sequence that is at least 95% identical to SEQ ID NO: 3,

wherein the adenoviral vector requires complementation of a deficiency in one or more early regions of the adenoviral genome for propagation and does not require complementation of any other deficiency of the adenoviral genome for propagation.

14. The method of claim 13 , wherein the portion of adenovirus serotype 45 hexon protein is encoded by the nucleic acid sequence of SEQ ID NO: 2.

15. The method of claim 13 , wherein the portion of adenovirus serotype 45 fiber protein is encoded by the nucleic acid sequence of SEQ :ID NO: 4.

16. The method of claim 13 , wherein the replication-deficient serotype 28 adenoviral vector comprises:

(a) an amino acid sequence of a serotype 28 adenovirus penton protein,

(b) an amino acid sequence of a serotype 28 adenovirus pIX protein,

(c) an amino acid sequence of a serotype 28 adenovirus p100 protein,

(d) an amino acid sequence of a serotype 28 adenovirus L1 52/55K protein, or

(e) any combination of (a)-(d).

17. The method of claim 13 , wherein the one or more early regions that the replication-deficient serotype 28 adenoviral vector requires for complementation are selected from the group consisting of the E1 region, the E2 region, and the E4 region of the adenovirus genome.

18. The method of claim 17 , wherein the replication-deficient serotype 28 adenoviral vector requires complementation of a deficiency in the E1 region of the adenoviral genome for propagation and does not require complementation of any other deficiency of the adenoviral genome for propagation.

19. The method of claim 13 , wherein the replication-deficient serotype 28 adenoviral vector comprises the nucleic acid sequence of SEQ ID NO: 10.

Assignments (1)
PATENT SECURITY AGREEMENT Recorded Sep 3, 2025
From: PRECIGEN, INC.; GENVEC LLC; PRECIGEN ACTOBIO, INC.; EXEMPLAR GENETICS, LLC
To: BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT
Reel/Frame 072828/0564 →
Continuity (3)
Continuation 14403651
Provisional Application 61652407 · May 29, 2012
Related Publication 20180100164A1 · Apr 12, 2018